Zymeworks, Inc. (ZYME)
29.19
-0.71
(-2.37%)
USD |
NASDAQ |
Sep 04, 16:00
29.20
+0.01
(+0.03%)
After-Hours: 20:00
Zymeworks Research and Development Expense (Quarterly) : 27.44M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 27.44M |
| March 31, 2026 | 34.46M |
| December 31, 2025 | 31.24M |
| September 30, 2025 | 35.58M |
| June 30, 2025 | 34.45M |
| March 31, 2025 | 35.74M |
| December 31, 2024 | 37.06M |
| September 30, 2024 | 36.35M |
| June 30, 2024 | 29.16M |
| March 31, 2024 | 32.04M |
| December 31, 2023 | 25.52M |
| September 30, 2023 | 32.78M |
| June 30, 2023 | 39.41M |
| March 31, 2023 | 45.91M |
| December 31, 2022 | 52.97M |
| September 30, 2022 | 37.10M |
| June 30, 2022 | 56.02M |
| March 31, 2022 | 62.51M |
| December 31, 2021 | 54.86M |
| September 30, 2021 | 49.89M |
| June 30, 2021 | 50.71M |
| March 31, 2021 | 41.66M |
| December 31, 2020 | 39.26M |
| September 30, 2020 | 53.53M |
| June 30, 2020 | 39.22M |
| Date | Value |
|---|---|
| March 31, 2020 | 36.53M |
| December 31, 2019 | 45.39M |
| September 30, 2019 | 29.25M |
| June 30, 2019 | 23.78M |
| March 31, 2019 | 17.48M |
| December 31, 2018 | 14.09M |
| September 30, 2018 | 14.14M |
| June 30, 2018 | 15.37M |
| March 31, 2018 | 13.08M |
| December 31, 2017 | 12.02M |
| September 30, 2017 | 11.52M |
| June 30, 2017 | 8.289M |
| March 31, 2017 | 8.84M |
| December 31, 2016 | 7.653M |
| September 30, 2016 | 9.759M |
| June 30, 2016 | 10.22M |
| March 31, 2016 | 7.916M |
| December 31, 2015 | 7.987M |
| September 30, 2015 | 5.157M |
| June 30, 2015 | 7.141M |
| March 31, 2015 | 4.118M |
| December 31, 2014 | 2.024M |
| September 30, 2014 | 2.862M |
| June 30, 2014 | 3.125M |
| March 31, 2014 | 2.462M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Theravance Biopharma, Inc. | 4.345M |
| BridgeBio Pharma, Inc. | 149.45M |
| Aprea Therapeutics, Inc. | 2.462M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |